Alnylam® Pharmaceuticals...Michael Polydefkisl, Angela Dispenzieri2 IJohns Hopkins, Baltimore, MD,...

1

Transcript of Alnylam® Pharmaceuticals...Michael Polydefkisl, Angela Dispenzieri2 IJohns Hopkins, Baltimore, MD,...

Page 1: Alnylam® Pharmaceuticals...Michael Polydefkisl, Angela Dispenzieri2 IJohns Hopkins, Baltimore, MD, USA; 2Mayo Clinic, Rochester, MN, ... Further analysis by baseline risk factors

Alnylam 2015 PowerPoint - Jefferies Pharma.pdf · 2 Alnylam Forward Looking Statements ... PBO: 7.4 ± 6.9 . Drug: 2.3 ± 6.0 ... Co-inheritance of thrombophilic traits in hemophilia

Alnylam 2015 PowerPoint - Jefferies Pharma.pdf · 2 Alnylam Forward Looking Statements ... PBO: 7.4 ± 6.9 . Drug: 2.3 ± 6.0 ... Co-inheritance of thrombophilic traits in hemophilia

New Co-Ops & Summer Internships - Alnylam Pharmaceuticals · 2020. 10. 5. · contractor after my co-op ended, and I continue to learn and grow every day I’m here.” Victoria Guan,

New Co-Ops & Summer Internships - Alnylam Pharmaceuticals · 2020. 10. 5. · contractor after my co-op ended, and I continue to learn and grow every day I’m here.” Victoria Guan,

Alnylam Pharmaceuticals · 12 Patisiran Interim Phase 2 OLE Study Results* Ongoing Study in FAP Patients PLANNED NEXT STEPS 24-month Phase 2 OLE data • in mid-2016 *Preliminary

Alnylam Pharmaceuticals · 12 Patisiran Interim Phase 2 OLE Study Results* Ongoing Study in FAP Patients PLANNED NEXT STEPS 24-month Phase 2 OLE data • in mid-2016 *Preliminary

APPRAISAL OF ROCHESTER STATE HOSPITAL Rochester ...

APPRAISAL OF ROCHESTER STATE HOSPITAL Rochester ...

Alnylam Pharmaceuticals R&D · PDF fileNOAEL 6 mos Rat (mg/kg) NOAEL 9 mos NHP (mg/kg) Expected Human Therapeutic Index (TI)2 Rat NHP Rat NHP Revusiran3 30 ≥300 N/A N/A 30 ≥200

Alnylam Pharmaceuticals R&D · PDF fileNOAEL 6 mos Rat (mg/kg) NOAEL 9 mos NHP (mg/kg) Expected Human Therapeutic Index (TI)2 Rat NHP Rat NHP Revusiran3 30 ≥300 N/A N/A 30 ≥200

Fearless in Pharma AGENDA - Momentum Events · 2021. 6. 27. · Sara Nochur Chief Diversity, Equity and Inclusion Officer ALNYLAM PHARMACEUTICALS Deborah Dunsire, M.D. Chief Executive

Fearless in Pharma AGENDA - Momentum Events · 2021. 6. 27. · Sara Nochur Chief Diversity, Equity and Inclusion Officer ALNYLAM PHARMACEUTICALS Deborah Dunsire, M.D. Chief Executive

Colin Living with Porphyria - Alnylam Pharmaceuticals · 2020-04-18 · Colin Living with Porphyria Alnylam Pharmaceuticals 35th Annual J.P. Morgan Healthcare Conference January 9,

Colin Living with Porphyria - Alnylam Pharmaceuticals · 2020-04-18 · Colin Living with Porphyria Alnylam Pharmaceuticals 35th Annual J.P. Morgan Healthcare Conference January 9,

Scientific Advisory Committee Bios 3.24.2020 · 2020-03-24 · is a co-founder of Biogen and Alnylam Pharmaceuticals Inc. 2 Elizabeth H. Blackburn, PhD ... uncover the genetic origins

Scientific Advisory Committee Bios 3.24.2020 · 2020-03-24 · is a co-founder of Biogen and Alnylam Pharmaceuticals Inc. 2 Elizabeth H. Blackburn, PhD ... uncover the genetic origins

MCC Students Succeed · PDF fileAzab, Yehia Rochester Aziz, Dilan Rochester Baackes, Margaret Rochester Babb, Elizabeth Rochester Bahai, Melle Rochester Bailey, Kyle Rochester Bailey,

MCC Students Succeed · PDF fileAzab, Yehia Rochester Aziz, Dilan Rochester Baackes, Margaret Rochester Babb, Elizabeth Rochester Bahai, Melle Rochester Bailey, Kyle Rochester Bailey,

SPECIAL NEWS ITEM - PBL Technology · Alnylam Pharmaceuticals, Inc. Plant Bioscience Limited here P B L N e w s-I s s u e 2 3-M a y 2 0 1 2 ... Alnylam and Isis co-founded Regulus

SPECIAL NEWS ITEM - PBL Technology · Alnylam Pharmaceuticals, Inc. Plant Bioscience Limited here P B L N e w s-I s s u e 2 3-M a y 2 0 1 2 ... Alnylam and Isis co-founded Regulus

Harnessing RNAi · Harnessing RNAi: Alnylam Pharmaceuticals is conquering rare diseases one drug at a time BUILDING A CANADIAN PRESENCE AND BEYOND “Having the opportunity to work

Harnessing RNAi · Harnessing RNAi: Alnylam Pharmaceuticals is conquering rare diseases one drug at a time BUILDING A CANADIAN PRESENCE AND BEYOND “Having the opportunity to work

PowerPoint - 4x3 Arial - Alnylam® Pharmaceuticals Algorithm, Abbvie, Resverlogix, Cerenis Disclosures. 3 Background LDL-C variability common, associated with worse outcomes . …

PowerPoint - 4x3 Arial - Alnylam® Pharmaceuticals Algorithm, Abbvie, Resverlogix, Cerenis Disclosures. 3 Background LDL-C variability common, associated with worse outcomes . …

Fitusiran - Alnylam® Pharmaceuticals · those risks more fully discussed in our most recent quarterly report on Form 10-Q under the caption “Risk Factors.”If one or more of these

Fitusiran - Alnylam® Pharmaceuticals · those risks more fully discussed in our most recent quarterly report on Form 10-Q under the caption “Risk Factors.”If one or more of these

Alnylam Assist® Services Overview for HCPs · Services Overview Alnylam Assist® offers a wide range of services to guide your patients through treatment with ONPATTRO® (patisiran)

Alnylam Assist® Services Overview for HCPs · Services Overview Alnylam Assist® offers a wide range of services to guide your patients through treatment with ONPATTRO® (patisiran)

Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN · PDF fileTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT ALNY - Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-AT3 for the treatment

Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN · PDF fileTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT ALNY - Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-AT3 for the treatment

Corporate Overview - Alnylam Pharmaceuticals › web › assets › ALNY-CorpDeck-PRES-Sept… · Corporate Overview . Alnylam Forward Looking Statements 2 This presentation contains

Corporate Overview - Alnylam Pharmaceuticals › web › assets › ALNY-CorpDeck-PRES-Sept… · Corporate Overview . Alnylam Forward Looking Statements 2 This presentation contains

Investor Presentation · 2020. 9. 8. · NTT DaTa! ãÌ LPL Financial OSONNËV Alnylam PHARMACEUTICALS PAN SVUNCECOì&ANY A member of the Pan-American Insurance Group ) DOORDASH „wayfair!

Investor Presentation · 2020. 9. 8. · NTT DaTa! ãÌ LPL Financial OSONNËV Alnylam PHARMACEUTICALS PAN SVUNCECOì&ANY A member of the Pan-American Insurance Group ) DOORDASH „wayfair!

Advances in RNAi Therapeutics Platform · 2019-12-14 · 3 Founded on the Bold Promise of Turning Nobel Prize Winning Science into a New Class of Medicine Alnylam Pharmaceuticals

Advances in RNAi Therapeutics Platform · 2019-12-14 · 3 Founded on the Bold Promise of Turning Nobel Prize Winning Science into a New Class of Medicine Alnylam Pharmaceuticals

210922Orig1s000 - Food and Drug Administration · Alnylam Pharmaceuticals Inc. (Alnylam) submitted a New Drug Application ... of the FD&C Act: FDAAA factor (F): ... The clinical presentation

210922Orig1s000 - Food and Drug Administration · Alnylam Pharmaceuticals Inc. (Alnylam) submitted a New Drug Application ... of the FD&C Act: FDAAA factor (F): ... The clinical presentation

2020 Alnylam Rare Disease Trend Report...7 PERSPECTIVES FROM HEALTHCARE PAYERS 2020 Alnylam Rare Disease Trend Report Rare diseases are defined by the U.S. Food & Drug Administration

2020 Alnylam Rare Disease Trend Report...7 PERSPECTIVES FROM HEALTHCARE PAYERS 2020 Alnylam Rare Disease Trend Report Rare diseases are defined by the U.S. Food & Drug Administration